Výsledky vyhledávání - "lutetium 177"

Akademický článek

Production and evaluation of cellular effects of 153Sm-DOTA-cetuximab and 177Lu-DOTA-cetuximab radioconjugates

Publikováno v: مجله علوم و فنون هسته‌ای, Vol 44, Iss 3, Pp 171-179 (2023)

Antibody-based radiopharmaceuticals are of increasing interest today in cancer imaging and radiotherapy. The cetuximab monoclonal antibody binds to the epidermal growth factor receptor (EGFR) and thus provides therapeutic and diagnostic protocols aga

Externí odkaz: https://doaj.org/article/87b4a11c396d4417a0d3d6a291dc5c61

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far

Autor: Ken Herrmann, Koen Vermeulen, An Aerts, Nathalie Heynickx, Sarah Baatout

Publikováno v: NUCLEAR MEDICINE AND BIOLOGY

At present, prostate cancer remains the second most occurring cancer in men, in Europe. Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration-resistant prostate cancer in particular is limited. Prostate-specific mem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15043b2fcdb486077d8454d818ae7171
https://doi.org/10.1016/j.nucmedbio.2021.04.003

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

HEDEFE YÖNELİK TEDAVİDE GÜNCEL YAKLAŞIMLAR: LUTESYUM-177 İLE İŞARETLİ RADYOFARMASÖTİKLER

Autor: Hişir D., Ekinci M., Ilem-Özdemir D.

Objective: In recent years, thanks to advances in targeted radionuclide therapy, significant advances have been made in the early diagnosis and treatment of diseases. With the emergence of the concept of "theranostic", which combines diagnosis and tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______9436::d6953e16bbd5cec9fd8798affea906bb
https://hdl.handle.net/11454/79907

Zobrazit plný text záznamu

Pre-Study on Radiolabeling of Colistin with Lutetium-177 to Develop Theranostic Infection Agent

Autor: Merve KARPUZ, Emre OZGENC, Evren ATLIHAN GUNDOGDU, Zeynep BURAK

Infection is one of the important burdens on the health care system, not only due to leading morbidity and mortality but also because of the development of antibiotic resistance. Although the infection can be diagnosed by imaging techniques, more eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42c52240c07e48f300f153bd505ccb0d
https://hdl.handle.net/11454/79877

Zobrazit plný text záznamu

Obtenção de kit de PSMA-617 para pronta marcação com lutécio-177 e sua avaliação na aplicabilidade no tratamento do câncer de próstata

Autor: Cristian A.W.V. Boas

Publikováno v: Biblioteca Digital de Teses e Dissertações da USP
Universidade de São Paulo (USP)
instacron:USP
Repositório Institucional do IPEN
Instituto de Pesquisas Energéticas e Nucleares (IPEN)
instacron:IPEN

O câncer de próstata é o segundo tipo de neoplasia que mais afeta homens no Brasil. De acordo com o Instituto Nacional de Câncer (INCA), em 2020 surgirão mais de 65 mil novos casos desta doença. Uma via eficiente para o tratamento deste câncer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c367115ed56d3e8d028aaa64c3aac12

Zobrazit plný text záznamu

Development of radioimmunoconjugates as theranostic agents based on the anti-HER2 monoclonal antibody (trastuzumab): influence of chelating agents and radionuclides on biological properties

Autor: MIRANDA, ANA C.C.

Publikováno v: Repositório Institucional do IPEN
Instituto de Pesquisas Energéticas e Nucleares (IPEN)
instacron:IPEN

Submitted by Pedro Silva Filho (pfsilva@ipen.br) on 2021-09-10T19:02:04Z No. of bitstreams: 0 Made available in DSpace on 2021-09-10T19:02:04Z (GMT). No. of bitstreams: 0 O c??ncer de mama ?? a segunda maior causa de mortalidade no mundo. Os tumores

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::d642ea127259fe667fcc84378eb725f7
http://repositorio.ipen.br/handle/123456789/32247

Zobrazit plný text záznamu

Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen

Autor: Carpanese, Debora, Ferro-Flores, Guillermina, Ocampo-Garcia, Blanca, Santos-Cuevas, Clara, Salvarese, Nicola, Figini, Mariangela, Fracasso, Giulio, De Nardo, Laura, Bolzati, Cristina, Rosato, Antonio, Meléndez-Alafort, Laura

Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Scientific Reports
Scientific reports (Nature Publishing Group) 10 (2020): 9313-1–9313-10. doi:10.1038/s41598-020-66285-2
info:cnr-pdr/source/autori:Carpanese D.; Ferro-Flores G.; Ocampo-Garcia B.; Santos-Cuevas C.; Salvarese N.; Figini M.; Fracasso G.; De Nardo L.; Bolzati C.; Rosato A.; Melendez-Alafort L./titolo:Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen/doi:10.1038%2Fs41598-020-66285-2/rivista:Scientific reports (Nature Publishing Group)/anno:2020/pagina_da:9313-1/pagina_a:9313-10/intervallo_pagine:9313-1–9313-10/volume:10

The clinical translation of theranostic 177Lu-radiopharmaceuticals based on inhibitors of the prostate-specific membrane antigen (PSMA) has demonstrated positive clinical responses in patients with advanced prostate cancer (PCa). However, challenges

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::aa4e7f621bbbbd0ffc42c9c964b10c2c
http://hdl.handle.net/11562/1019409

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání